NewLink Genetics Corp. Hits New 52-Week High at $24.50 (NLNK)
Shares of NewLink Genetics Corp. (NASDAQ:NLNK) hit a new 52-week high on Friday, Stock Ratings News reports. The company traded as high as $24.50 and last traded at $24.12, with a volume of 274,397 shares trading hands. The stock had previously closed at $23.36.
Separately, analysts at Stifel Nicolaus raised their price target on shares of NewLink Genetics Corp. from $28.00 to $31.00 in a research note to investors on Friday, December 13th. They now have a “buy” rating on the stock. Five equities research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and a consensus price target of $26.80.
NewLink Genetics Corp. has a 52 week low of $11.19 and a 52 week high of $23.76. The stock has a 50-day moving average of $21.98 and a 200-day moving average of $19.03. The company’s market cap is $638.5 million.
NewLink Genetics Corp. (NASDAQ:NLNK) last issued its quarterly earnings data on Monday, November 11th. The company reported ($0.32) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.33) by $0.01. During the same quarter last year, the company posted ($0.28) earnings per share. On average, analysts predict that NewLink Genetics Corp. will post $-1.29 earnings per share for the current fiscal year.
NewLink Genetics Corporation operates as a biopharmaceutical company. The Company, based in the United States, is focused on discovering, developing, and commercializing immunotherapeutic products to improve cancer treatment options for patients and physicians.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.